Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06440980
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-05-29
Brief Title:
A Study to Compare Tablets and Capsules of Orforglipron LY3502970 in Healthy Participants Who Are Obese or Overweight
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron LY3502970 Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to see how much of orforglipron study drug gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants The safety and tolerability side effects of orforglipron when given as capsules and tablets will also be evaluated
The study will be conducted in two parts with part A and B lasting up to approximately 25 and 22 weeks each respectively including the screening period
The study will be conducted in two parts with part A and B lasting up to approximately 25 and 22 weeks each respectively including the screening period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2A-MC-GZPI | OTHER | Eli Lilly and Company | None |